Abbott Laboratories (ABT) — Institutional Investor Activity (Q2 2026)

ABT ranks #56 out of 37696 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

3001 institutions disclose a position in ABT, but none treat it as a major bet — even Flossbach Von Storch Se, its most concentrated holder, allocates just 4.1% of its own portfolio to it.

DAVENPORT & Co LLC has added to its ABT position for two straight quarters, increasing it by $82.7M to reach $180.1M today.

Vontobel Holding Ltd. has trimmed its ABT position for two straight quarters, cutting it by $265.3M while still holding $16.5M.

ABT is up 0.2% today, and institutions have been net buyers of $25.8B this quarter — today's price move and the underlying institutional flow are pointing the same direction.

ABT posted net income of $6.3B over the trailing twelve months, and currently trades at a P/E of 29.2.

• Profitable — net income of $6.3B over the trailing twelve months
• Revenue grew 6.6% year over year
• Net income declined year over year, from $13.5B to $6.3B
• Generated $9.6B in positive operating cash flow
• Current ratio of 1.58x — enough short-term assets to cover short-term liabilities